BackPDL Biopharma Overview

PDL Biopharma Other Current Liabilities

PDL Biopharma's other current liabilities is $16M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$15.77M
↓ 31.11% YoYΔ $-7.12M vs prior year quarter

Peer trimmed avg / median

Loading

PDL Biopharma Other Current Liabilities History

Loading

PDL Biopharma vs. peers: Other Current Liabilities Comparison

Loading

PDL Biopharma Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PDL Biopharma (PDLI) FAQ

As of the most recent data (September 2020), PDLI shows a other current liabilities of $16M. That compares with $23M in the prior-year period — down 31.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PDLI's other current liabilities is now $16M (was $23M) — a 31.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.

Tracking PDLI's other current liabilities over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $23M in the prior-year period — down 31.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $16M) with ownership activity and broader fundamentals.

PDL Biopharma's other current liabilities is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.